These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 21394567)

  • 1. Impact of Different Fludarabine Doses in the Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation.
    Kuriyama K; Fuji S; Ito A; Doki N; Katayama Y; Ohigashi H; Nishida T; Serizawa K; Eto T; Uchida N; Kanda Y; Tanaka M; Matsuoka KI; Nakazawa H; Kanda J; Fukuda T; Atsuta Y; Ogata M
    Transplant Cell Ther; 2024 May; 30(5):514.e1-514.e13. PubMed ID: 38373522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model.
    Dighe NM; Tan KW; Tan LG; Shaw SSW; Buckley SMK; Sandikin D; Johana N; Tan YW; Biswas A; Choolani M; Waddington SN; Antoniou MN; Chan JKY; Mattar CNZ
    Exp Hematol; 2018 Jun; 62():45-55. PubMed ID: 29605545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.
    Nakane T; Nakamae H; Yamaguchi T; Kurosawa S; Okamura A; Hidaka M; Fuji S; Kohno A; Saito T; Aoyama Y; Hatanaka K; Katayama Y; Yakushijin K; Matsui T; Yamamori M; Takami A; Hino M; Fukuda T
    Int J Hematol; 2017 Apr; 105(4):485-496. PubMed ID: 27943166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin Enhanced Busulfan-Induced Apoptosis through Downregulating the Expression of Survivin in Leukemia Stem-Like KG1a Cells.
    Weng G; Zeng Y; Huang J; Fan J; Guo K
    Biomed Res Int; 2015; 2015():630397. PubMed ID: 26557682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
    Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.
    Nakane T; Nakamae H; Koh H; Nakamae M; Hayashi Y; Nishimoto M; Yoshimura T; Inoue E; Inoue A; Aimoto R; Aimoto M; Terada Y; Koh KR; Yamane T; Hino M
    Int J Hematol; 2011 Apr; 93(4):509-516. PubMed ID: 21394567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
    Modi D; Singh V; Kim S; Ayash L; Deol A; Ratanatharathorn V; Uberti JP
    Ann Hematol; 2021 Apr; 100(4):969-978. PubMed ID: 33594448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
    Kröger N; Shimoni A; Schilling G; Schwerdtfeger R; Bornhäuser M; Nagler A; Zander AR; Heinzelmann M; Brand R; Gahrton G; Morris C; Niederwieser D; de Witte T
    Br J Haematol; 2010 Jan; 148(2):323-31. PubMed ID: 19912215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the intensity of conditioning regimens: working definitions.
    Bacigalupo A; Ballen K; Rizzo D; Giralt S; Lazarus H; Ho V; Apperley J; Slavin S; Pasquini M; Sandmaier BM; Barrett J; Blaise D; Lowski R; Horowitz M
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1628-33. PubMed ID: 19896087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
    Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.